Corbus Pharmaceuticals Holdings, Inc.

Corbus Pharmaceuticals Holdings, Inc.

Biotechnology • Healthcare • Norwood, MA, United States • CRBP (NCM)

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

617 963 0100 500 River Ridge Drive, Norwood, MA 02062, United States

Stock Performance (90 Days)

Data through Dec 26, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

While hedge funds own 24% of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), retail investors are its largest shareholders with 46% ownership - Yahoo Finance
Yahoo Finance • Dec 27
How Corbus Pharmaceuticals Holdings Inc. (CRBP) Affects Rotational Strategy Timing - Stock Traders Daily
Stock Traders Daily • Dec 24
Corbus Pharmaceuticals (NASDAQ:CRBP) Shares Cross Below Fifty Day Moving Average - Should You Sell? - MarketBeat
MarketBeat • Dec 23
Corbus Pharmaceuticals: Is Its Pipeline Really Worthless After Novo's Negative Data? - Seeking Alpha
Seeking Alpha • Jun 17
Corbus Pharmaceuticals stock plunges after $75 million public offering - Investing.com
Investing.com • Oct 31

Other Biotechnology Companies

View All →
CODEXIS, INC. logo Codexis, Inc.
1 layoff tracked
$144.5M market cap
VERTEX PHARMACEUTICALS INC / MA logo Vertex Pharmaceuticals Inc. / MA
$118.68B market cap
REGENERON PHARMACEUTICALS, INC. logo Regeneron Pharmaceuticals, Inc.
$82.72B market cap
ALNYLAM PHARMACEUTICALS, INC. logo Alnylam Pharmaceuticals, Inc.
$52.92B market cap
ARGENX SE logo Argenx SE
$52.62B market cap
INSMED Inc logo Insmed Inc.
$37.61B market cap

Frequently Asked Questions

Has Corbus Pharmaceuticals Holdings, Inc. had layoffs?
No layoff events have been recorded for Corbus Pharmaceuticals Holdings, Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does Corbus Pharmaceuticals Holdings, Inc. have?
Corbus Pharmaceuticals Holdings, Inc. has approximately 28 employees.
What industry is Corbus Pharmaceuticals Holdings, Inc. in?
Corbus Pharmaceuticals Holdings, Inc. operates in the Biotechnology industry, within the Healthcare sector.
Is Corbus Pharmaceuticals Holdings, Inc. a publicly traded company?
Yes, Corbus Pharmaceuticals Holdings, Inc. is publicly traded under the ticker symbol CRBP on the NCM. The company has a market capitalization of approximately $0.15 billion.
Where is Corbus Pharmaceuticals Holdings, Inc. headquartered?
Corbus Pharmaceuticals Holdings, Inc. is headquartered in Norwood, MA, United States at 500 River Ridge Drive, Norwood, MA 02062, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.